Navigation Links
Cepheid Announces Board of Directors Changes
Date:2/14/2013

SUNNYVALE, Calif., Feb. 14, 2013 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that its Board of Directors has elected John Bishop as Chairman of the Board of Directors and named Cristina Kepner as Lead Independent Director, effective February 12, 2013.

Mr. Bishop, currently Cepheid's Chief Executive Officer, succeeds Thomas Gutshall , who will continue to serve on Cepheid's board as a director.  Mr. Bishop has been Cepheid's Chief Executive Officer and a director since April 2002.

"It is an honor to succeed Tom Gutshall as Chairman of Cepheid," said John Bishop .  "Since 1996, Tom has contributed immeasurably to Cepheid's vision and direction, as co-founder and Chairman of the Board and as our original Chief Executive Officer.  In addition to his breadth of experience in life sciences, Tom brings his deep experience with our proprietary technologies, and I look forward to his continuing contributions as a director."

" Cris Kepner has been a significant contributor on the Cepheid Board for 15 years," added John Bishop .  "Given her background and tenure on the Board, Cris brings broad market knowledge as well as a deep understanding of Cepheid, which will be ever more valuable in her role as Lead Independent Director."

Newly appointed Lead Independent Director Cristina Kepner has been a Cepheid director since 1998.  Ms. Kepner was formerly Executive Vice President and Corporate Finance Director of Invemed Associates, an investment bank, where she worked for 22 years.  Additionally, Ms. Kepner served as a director of Monogram Biosciences Inc. from May 1996 until August 2009, and as a director and later Chairman of the board of directors of Quipp, Inc. from January 1995 until June 2008.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400 8377

communications@cepheid.com

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400 8329

investor.relations@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Welcomes Senior Vice President of Human Resources
2. Cepheid Reports Fourth Quarter and Full Year 2011 Results
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
5. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
6. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
7. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
8. Cepheid Reports 2012 Second Quarter Results
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
10. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):